Hi guys, Welcome to the Advanced Video Search Engine, and you are watching DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer. That video is uploaded by VJOncology at 2021-10-06T03:31:50-07:00. We are promoting this video only for entertainment and educational purpose only. So, I hope you like & enjoy it. [pdnAQw6Vi-E]
| Name | DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer |
| Video Uploader | Video From VJOncology |
| Upload Date | This Video Uploaded At 06-10-2021 10:31:50 |
| Video Discription | Elizabeth Smyth, MD, Cambridge University Hospitals, Cambridge, UK, summarises the rationale and results of the DESTINY-Gastric02 trial (NCT04014075). This was a non-randomised Phase II trial of trastuzumab deruxtecan (T-Dxd) as a second-line treatment for patients with HER2-positive gastric cancer. The overall response rate, which was the primary endpoint, was 38%, with a duration of response of more than 8 months. The treatment was well-tolerated and encouraging results were achieved. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress. pdnAQw6Vi-E |
| Category | Education |
| Tags | Speaker: Elizabeth C. Smyth | Institution: Cambridge University Hospitals | Event: ESMO 2021 | Event: VJVirtual | Format: Interview | Subject: Gastric Cancer | Field: Treatment | Field: Trial Updates | Field: Immuno-Oncology | Subject: Gastrointestinal Cancer | Medicines: Antibodies | Medicines: Trastuzumab deruxtecan | Trial: DESTINY-Gastric02 | NCT04014075 | Medicines: Paclitaxel | Medicines: Ramucirumab |
